Bioalliance PharmaAct Nom. Cat-P News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

20.05.15	Onxeo: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at April 30, 2015 (Businesswire)
12.05.15	Onxeo S.A.: Publication of a Letter to Shareholders – May 2015 (Businesswire)
06.05.15	Onxeo : Oral Presentation of Phase II Trial Results of Validive® at the MASCC/ISOO International Symposium (Businesswire)
20.04.15	Onxeo: Belinostat Abstracts for American Association for Cancer Research 2015 (Businesswire)
16.04.15	Onxeo S.A.: ReLive: investigators meeting and E-poster of the study design during the 2015 EASL congress (Businesswire)
15.04.15	Onxeo S.A.: Quarterly Information as of March 31, 2015 (Businesswire)
15.04.15	Onxeo: Annual General Shareholders’ Meeting: Results and Convening to a New Meeting (Businesswire)
14.04.15	Onxeo S.A.: Publication of 2014 Reference Document and Annual Report (Businesswire)
13.04.15	Onxeo: Cipher Pharmaceuticals Acquires INNOCUTIS Holdings, Licensee of Sitavig® in the USA (Businesswire)
13.04.15	Onxeo Announces 6th Positive DSMB Recommendation for Livatag® ReLive Study in HCC (Businesswire)
09.04.15	Onxeo: Belinostat Phase I/II Results in Soft Tissue Sarcoma to Be Presented at the 2015 Annual ASCO Meeting (Businesswire)
02.04.15	Onxeo: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at March 31, 2015 (Businesswire)
02.04.15	Onxeo S.A.: Phase II trial results of Validive® presented at the ASCO Conference (Businesswire)
31.03.15	Onxeo S.A.: Judith Greciet, invited as guest speaker at international Allicense Conference (Businesswire)
26.03.15	Onxeo Expands Livatag® International Phase III Clinical Trial "ReLive” to 3 New Countries (Businesswire)
25.03.15	Onxeo: Combined Ordinary and Extraordinary General Meeting on April 15, 2015 (Businesswire)
18.03.15	ONXEO Consolidates Its Intellectual Property with the Grant of New Patent Protection of Validive® in Japan Until 2029 (Businesswire)
05.03.15	Onxeo: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at February 28, 2015 (Businesswire)
04.03.15	2014 Onxeo Review and 2015 Perspectives (Businesswire)
10.02.15	Onxeo Strengthens Its Executive Management Team (Businesswire)
06.02.15	Onxeo : Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at January 31, 2015 (Businesswire)
28.01.15	Onxeo S.A.: Publication of a Shareholders Letter (Businesswire)
26.01.15	Onxeo’s Shares Transferred to Compartment B on Euronext Paris (Businesswire)
16.01.15	Onxeo Announces Its Financial Calendar for 2015 (Businesswire)
08.01.15	Onxeo to Present at Biotech Showcase™ Annual Conference during JP Morgan Healthcare Conference (Businesswire)
07.01.15	Onxeo : Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at December 31, 2014 (Businesswire)
16.12.14	Onxeo Announces the Realization of Its Share Capital Increase with Shareholders’ Preferential Subscription Rights (Businesswire)
12.12.14	Onxeo Announces the Great Success of Its Share Capital Increase with Shareholders’ Preferential Subscription Rights (Businesswire)
03.12.14	Onxeo : Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at November 30, 2014 (Businesswire)
24.11.14	Onxeo Announces Positive DSMB Recommendation for Its Phase III Trial with Livatag® in Primary Liver Cancer (Businesswire)
18.11.14	ONXEO Launches a Rights Issue with Shareholder Preferential Subscription Rights, for a Maximum Amount of up to €41.6 Million (Including an Extension Clause of €5.3 Million) (Businesswire)
13.11.14	Onxeo Confirms Receipt of the $25M Milestone Payment on Beleodaq® (Businesswire)
05.11.14	Onxeo: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at October 31, 2014 (Businesswire)
30.10.14	Onxeo S.A.: Positive Phase II preliminary results of Validive® For the prevention of Severe Oral Mucositis in Head and Neck cancer patients (Businesswire)
10.10.14	Onxeo reaches second milestone of BPIFrance grant dedicated to Livatag® development as part of NICE Consortium (Businesswire)
03.10.14	Capital Increase in Onxeo as a Result of Employee Warrant Exercise (Businesswire)
02.10.14	Onxeo : Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at September 30, 2014 (Businesswire)
25.09.14	Corporate Governance prize awarded by AGEFI: Onxeo receives "Silver Governance” (Businesswire)
24.09.14	Onxeo announces participation in the Midcap Event On October 2nd and 3rd, 2014 in Paris (GlobeNewswire)
24.09.14	Onxeo Announces Participation in the Midcap Event on October 2nd and 3rd, 2014 in Paris (Businesswire)
19.09.14	Onxeo Attends InvestorDagen 2014, the Largest Danish Private Investor Event (Businesswire)
04.09.14	Onxeo: Disclosure of total number of voting rights and number of shares in the capital at August 31, 2014 (Businesswire)
28.08.14	Onxeo Strengthens Beleodaq® Patent Protection in the U.S. Until 2027 (Businesswire)
01.08.14	Onxeo SA: Key milestones and consolidated accounts First six months 2014 (Businesswire)
24.07.14	BioAlliance Pharma: Approval of Onxeo’s admission to secondary listing and trading on NASDAQ OMX Copenhagen (Businesswire)
23.07.14	The cross-border merger of BioAlliance Pharma and Topotarget is legally effective as of 22 July 2014 (Businesswire)
21.07.14	BioAlliance Pharma Announces the Launch of Sitavig® in the United States by Its Partner Innocutis (Businesswire)
18.07.14	BioAlliance Pharma Strengthens Its Financial Resources with the Support of Its Top Shareholder (Businesswire)
03.07.14	BioAlliance Pharma: FDA approval of Beleodaq™ (belinostat) (Businesswire)
03.07.14	BioAlliance Pharma: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at June 30, 2014 (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu Bioalliance PharmaAct Nom. Cat-P

Aktien Top/Flop

Meistgelesene Nachrichten